Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19

Objective: Soluble CD163 (sCD163) is a biomarker involved in inflammation. There is little data on the prognostic utility of sCD163 in coronavirus disease-2019 (COVID-19). This study investigated the relationship between serum sCD163 and the prognosis of COVID-19. Methods: A total of 79 hospitalized patients diagnosed with COVID-19 were included in this retrospective study. Patients were divided into two groups as survivors and non-survivors. The clinical characteristics, serum sCD163 level, and other laboratory data of patients were compared between the groups. Results: Forty-two (53.2%) of the 79 cases were male. The mean age was 70.4±12 years in the non-survivor group and 64.2±14 years in the survivor group (p=0.079). Serum sCD163, prothrombin time, and lactate were significantly higher in non-survivors than in survivors (p=0.023, p=0.015, p=0.018, respectively). The optimum cutoff value of serum sCD163 by receiver operating curve analysis was 2.92 ng/mL, resulting in 74% sensitivity and 52% specificity for predicting mortality (area under the curve: 0.620, 95% confidence interval: 0.481-0.759, p=0.048). Serum sCD163≥2.92 ng/mL was associated with 4.3 times higher mortality risk as assessed by logistic regression analysis (p=0.014). Conclusion: sCD163 is an independent predictor of mortality in COVID-19 positive patients who have a fatal course of the disease.

Anahtar Kelime: Soluble CD163 COVID-19 inflammation mortality

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect 2020;53:404-12.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
Madsen M, Møller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T,et al. Molecular characterization of the haptoglobin. hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem 2004;279:51561-7.
Møller HJ, Nielsen MJ, Maniecki MB, Madsen M, Moestrup SK. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology 2010;215:406-12.
Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007;178:8183-94.
Van Gorp H, Van Breedam W, Delputte PL, Nauwynck HJ. Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. J Gen Virol 2008;89:2943-53.
Møller HJ. Soluble CD163. Scand J Clin Lab Invest 2012;72:1-13.
Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.
BaetenD,MøllerHJ,DelangheJ,VeysEM,MoestrupSK,DeKeyser F. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004;50:1611-23.
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011;52:643-50.
Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology 2014;60:521-30.
Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, et al. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med 2006;34:2561-6.
Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV- infected patients. J Infect Dis 2011;204:1227-36.
Nalbant A, Kaya T, Varim C, Yaylaci S, Tamer A, Cinemre H. Can the neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)? Rev Assoc Med Bras (1992) 2020;66:746-51.
Generoso M, Álvarez P, Kravietz A, Mwamzuka M, Marshed F, Ahmed A, et al. High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection. AIDS 2020;34:33-8.
Ye H, Wang LY, Zhao J, Wang K. Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure. World J Gastroenterol 2013;19:2818-25.
Kjærgaard AG, Rødgaard-Hansen S, Dige A, Krog J, Møller HJ, Tønnesen E. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients. PLoS One 2014;9:e92331.
Knudsen TB, Ertner G, Petersen J, Møller HJ, Moestrup SK, Eugen- Olsen J, et al. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. J Infect Dis 2016;214:1198-204.
Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Rodríguez-Tenreiro C, et al. Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology. Front Immunol 2020;11:560381.
Bowman ER, Cameron CMA, Avery A, Gabriel J, Kettelhut A, Hecker M, et al. Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019. J Infect Dis 2021;223:805-10.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
Fadel FA, Al-Jaghbeer M, Kumar S, Griffiths L, Wang X, Han X, et al. Clinical characteristics and outcomes of critically Ill patients with COVID-19 in Northeast Ohio: low mortality and length of stay. Acute Crit Care 2020;35:242-8.

APA	nalbant a, Kaya T, YAYLACI S, çekiç d, ÖZMEN SÜNER K, Karacaer C, ÇOKLUK e, Bilgin C (2022). Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. , 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
Chicago	nalbant ahmet,Kaya Tezcan,YAYLACI Selçuk,çekiç deniz,ÖZMEN SÜNER KEZBAN,Karacaer Cengiz,ÇOKLUK erdem,Bilgin Cahit Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. (2022): 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
MLA	nalbant ahmet,Kaya Tezcan,YAYLACI Selçuk,çekiç deniz,ÖZMEN SÜNER KEZBAN,Karacaer Cengiz,ÇOKLUK erdem,Bilgin Cahit Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. , 2022, ss.42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
AMA	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. . 2022; 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
Vancouver	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. . 2022; 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
IEEE	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C "Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19." , ss.42 - 47, 2022. 10.4274/BMJ.galenos.2022.2022.2-5
ISNAD	nalbant, ahmet vd. "Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19". (2022), 42-47. https://doi.org/10.4274/BMJ.galenos.2022.2022.2-5

APA	nalbant a, Kaya T, YAYLACI S, çekiç d, ÖZMEN SÜNER K, Karacaer C, ÇOKLUK e, Bilgin C (2022). Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. Bakırköy Tıp Dergisi, 18(3), 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
Chicago	nalbant ahmet,Kaya Tezcan,YAYLACI Selçuk,çekiç deniz,ÖZMEN SÜNER KEZBAN,Karacaer Cengiz,ÇOKLUK erdem,Bilgin Cahit Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. Bakırköy Tıp Dergisi 18, no.3 (2022): 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
MLA	nalbant ahmet,Kaya Tezcan,YAYLACI Selçuk,çekiç deniz,ÖZMEN SÜNER KEZBAN,Karacaer Cengiz,ÇOKLUK erdem,Bilgin Cahit Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. Bakırköy Tıp Dergisi, vol.18, no.3, 2022, ss.42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
AMA	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. Bakırköy Tıp Dergisi. 2022; 18(3): 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
Vancouver	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19. Bakırköy Tıp Dergisi. 2022; 18(3): 42 - 47. 10.4274/BMJ.galenos.2022.2022.2-5
IEEE	nalbant a,Kaya T,YAYLACI S,çekiç d,ÖZMEN SÜNER K,Karacaer C,ÇOKLUK e,Bilgin C "Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19." Bakırköy Tıp Dergisi, 18, ss.42 - 47, 2022. 10.4274/BMJ.galenos.2022.2022.2-5
ISNAD	nalbant, ahmet vd. "Prognostic Significance of Soluble CD163 in Hospitalized Patients with COVID-19". Bakırköy Tıp Dergisi 18/3 (2022), 42-47. https://doi.org/10.4274/BMJ.galenos.2022.2022.2-5